Mediquo Is Committed to the International Market and Aims to Double Sales in 2024

Mediquo bases its growth strategy on the international market. The Spanish company, which offers medical consultations between the medical professional and the user, hopes to double its sales in 2024, to exceed €3 million, according to Guillem Serra, CEO of Mediquo.

The company currently operates in Spain, but has also begun to work in Brazil and Ecuador, countries in which it has managed to create a network of partners, where Mediquo has corporate clients, as well as local medical services.

By 2023, the company expects to invoice around €800,000, a figure that it expects to be between €1.5 million and €2 million in 2024. In Brazil, Mediquo expects to end the year with revenues of €800,000 and the forecast is to reach €2 million or €3 million next year. In Ecuador, at the moment the activity reports sales of €200,000.

Read more about Mediquo and find other important business news from around the world with the Born2Invest mobile app.

Mediquo offers telemedicine services for the insurer Asisa

Throughout 2023, Mediquo has closed agreements with different companies in the health sector, among which the insurer Asisa stands out, which has chosen the start-up as its service provider. In addition, the Spanish company has strengthened other collaborations, among which are the Capsbe Primary Care Centers (CatSalut), GSK, Novo Nordisk, AIG, and Inmedical, among others. The company does not rule out closing more agreements with other companies and insurers to be its telemedicine provider.

Mediquo makes it possible for any healthcare professional to care for their patients via chat, call or video call safely and with professional tools that facilitate telematic communication. Currently, the company has more than one million registered users on its platform and receives around 1.5 million queries annually.

Last April, the Catalan company closed its latest financing round of €1.3 million, which will precisely serve to strengthen its presence in Spanish territory and consolidate its internationalization in Latin America. The round was led by the Silanes Group, together with Encomenda, Trampoline Venture Partners, Capital Cell, and Tokavi.

The company has closed a financing round of €1.3 million this year

The company’s first round was closed in 2018 and the company raised three million euros. The economic injection was led by Leandro Sigman, president of Insud Pharma, a pharmaceutical multinational present in more than forty countries.

Also in 2018, Mediquo closed its second round, of €1.5 million. The capital increase was led by the venture capital firm Target Global, which has invested in companies such as Docplanner, a firm that merged with the Spanish digital health company Doctoralia, or Delivery Hero, a food delivery company.

The third round was in January 2020. The company obtained €2 million, through a financial contribution from the current partner, Target Global, and led by a Spanish investor specialized in health, whose identity was not revealed. In 2021, MediQuo had closed another round of one million euros led by the Mexican laboratory Silanes.

__

(Featured image by Tumisu via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.